The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2010Targeting the Unfolded Protein Response (UPR) Transcription Factor XBP-1 to Treat Parkinson's Disease
Objective/Rationale:
Our general objective is to investigate the role of a specific component of a cellular stress responses linked to organelle damage, the Unfolded Protein Response (UPR), in the... -
Target Validation, 2010Modulation of the Rho Kinase pathway for improvement of regeneration in PD
Objective/Rationale:
A characteristic feature of Parkinson’s disease is the loss of axons, the long processes of neuronal cells. This loss of axons seems to occur early in the course of the disease... -
Rapid Response Innovation Awards, 2010SNCA Haplotyping in Parkinson's Disease and Multiple System Atrophy
Objective/Rationale:
A succinct, lay-oriented statement of the scientific rationale for this project. We have recently shown that genetic variants at the SNCA gene locus, coding for the alpha-synuclein... -
Rapid Response Innovation Awards, 2010Resting State fMRI as a Biomarker for Parkinson's Disease
Objective/Rationale:
There is an increasingly interest in finding biomarkers that can objectively evaluate the disease progression and the effects of neuroprotective treatment on the course of... -
MJFF Research Grant, 2010Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism
Objective/Rationale:
Transgenic pre-clinical models are instrumental to investigate mutation-induced abnormalities at the bio-chemical, cellular level in a manner not possible in humans. In humans... -
Therapeutics Development Initiative, 2010Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease
Objective/Rationale:
Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons. No endogenous Nurr1 ligands have been identified, and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.